Onderneming Audentes Therapeutics, Inc.
Aandelen
US05070R1041
Biotechnologie & Medisch Onderzoek
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Andrew Krivoshik
PSD | President | - | - |
Morten Sogaard
COO | Chief Operating Officer | - | 01-05-22 |
Jason Schwartz
CTO | Chief Tech/Sci/R&D Officer | - | 01-06-22 |
David Smethurst
LAW | General Counsel | - | 01-08-21 |
Fulvio Mavilio
PRN | Corporate Officer/Principal | - | 18-07-17 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Kush Parmar
BRD | Director/Board Member | 42 | 01-07-13 |
Alan Beggs
BRD | Director/Board Member | - | - |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 45 783 265 | 42 304 829 ( 92,40 %) | 0 | 92,40 % |
Bedrijfsgegevens
Astellas Gene Therapies, Inc.
600 California Street 17th floor
94108, San Francisco
+415 818 1001
http://www.astellasgenetherapies.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+9,58% | 115 mld. | |
+12,41% | 106 mld. | |
-2,59% | 21,96 mld. | |
-12,38% | 21,87 mld. | |
-5,29% | 19,21 mld. | |
-3,35% | 18,08 mld. | |
-38,57% | 17,71 mld. | |
+7,51% | 14,32 mld. | |
+35,67% | 12,42 mld. |